Rezolute
IPOHypoglycemia & Hyperinsulinism | Ersodetug
Public · United States · $66.0M raised
- Business Model
- B2B
- Website
- rezolutebio.com
- Total Funding
- $66.0M
- Last Round
- $41.0M Private EquityOct 2020
- Rounds
- 2
- Type
- Public
About
Rare disease biotech developing ersodetug, a potential treatment for hypoglycemia caused by congenital and tumor hyperinsulinism.
Summary
Rezolute is a Biotech company based in United States. It has raised $66.0M in total across 2 rounds, most recently a $41.0M Private Equity round in Oct 2020. Investors include Handok Inc., CAM Capital and BVF Partners.
Tech & App Stack
3 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jan 2024
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...